Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot

See allHide authors and affiliations

Science Translational Medicine  02 Oct 2019:
Vol. 11, Issue 512, eaaw3163
DOI: 10.1126/scitranslmed.aaw3163

A vaccine to fight Lassa fever

Thousands of people in Western Africa succumb to Lassa fever each year. Lassa virus infections can in some cases respond to antiviral treatment, but there is no vaccine. Mateo et al. tested three different viral-vectored Lassa virus vaccines in a nonhuman primate model. They compared transcriptomic and proteomic signatures as well as B cell and T cell responses after vaccination. One vaccine using a measles virus vector with Lassa virus glycoprotein and nucleoprotein provided almost sterilizing protection upon a lethal Lassa virus challenge. This vaccine will soon be tested in humans and has the potential to make a major impact on the incidence of Lassa fever.

View Full Text

Stay Connected to Science Translational Medicine